Related Experiment Video
Updated: Aug 13, 2026
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Danger of systemic cyclosporine for corneal graft
Marie-Paule Algros1, Régis Angonin, Bernard Delbosc
1Department of Pathology, Jean Minjoz University Hospital, Boulevard A. Fleming, 25030 Besançon Cedex, France. ana-path@chu-besancon.fr
Purpose:
To report a case of posttransplant lymphoproliferative disorder (PTLD) in a patient receiving oral cyclosporine (CS) for immunosuppression in a high-risk keratoplasty.
Methods:
A systemic CS therapy was given to prevent graft rejection of a keratoplasty. Risk rejection was high in regard to a previous graft rejection and persistence of a corneal vascularization. One year after the keratoplasty, the patient developed a gastric Epstein-Barr virus (EBV)-induced B cell lymphoma. The outcome was favorable after chemotherapy.
Conclusions:
This unique case of lymphoma (PTLD) in the course of corneal graft management questions the indications and the follow-up of patients with CS therapy and raises the issue of topical CS treatment.
